demonstrate unprecedented improvements in clinical performance and reading
times, validating the substantial benefits of artificial intelligence when used
with 3D mammography

to showcase latest innovations in cancer detection at The European Society of
Breast Imaging annual meeting in booth 14

NASHUA, N.H. and ATHENS, Greece,
(October 11, 2018) – iCAD, Inc. (NASDAQ: ICAD), a global medical
technology leader providing innovative cancer detection and therapy solutions,
today announced outstanding clinical results of its new, leading-edge digital breast
tomosynthesis (DBT) cancer detection software. The study demonstrated
significant positive results for clinical performance and workflow efficiency.


The findings confirmed
that the latest artificial intelligence (AI) software solution to support DBT increased
improvements in both reader sensitivity (8.0 percent on average) and
specificity (6.9 percent on average). In addition, when reading tomosynthesis
cases with the solution, radiologists’ reading times were reduced by more than
half (52.7 percent on average). 


incidence rates of breast cancer continue to rise, we are proud to provide
valuable technology that is proven to significantly improve detection rates while reducing unnecessary recalls resulting from false
positives. We also understand that radiologists are concerned about the
extra workload and long reading times of tomosynthesis cases in everyday
practice and we are pleased to have created a meaningful solution to address
this problem,” said Jeff Hoffmeister, MD, Vice President and Medical Director
at iCAD. “As tomosynthesis moves into the screening arena, our AI software provides
important benefits to radiologists, their practices, and their patients.”


“iCAD’s unique technology assists me in detecting more
cancers, reassures me of my findings, and helps me concentrate on the essential
work of a radiologist. The product reduced my reading time by approximately 50
percent, allowing me to read these cases in nearly the same amount of time as
2D mammograms. I consider it to be one of the greatest tools in modern
radiology,” said Dr. Axel Gräwingholt, Radiologie am Theater, Paderborn, Germany.


high-performance, concurrent read, cancer detection and workflow solution for
breast tomosynthesis delivers critical benefits to both radiologists and their
patients. The new technology is trained to detect malignancies and determine
the probability of malignant findings, providing radiologists with a “certainty
of finding” score for each case and each detected lesion. These scores
represent the algorithm’s confidence that the detected soft tissue densities
(masses, architectural distortions and asymmetries) and calcifications are


receiving CE mark approval and showcasing our solution at the European Congress
of Radiology earlier this year, we’ve seen tremendous interest in our product
among European radiologists,” said Ken Ferry, CEO of iCAD. “We are proud to be
able to offer providers and patients alike greater access to an advanced breast
cancer detection solution that is proven to substantially increase cancer
detection performance and help to dramatically streamline workflows.”


revolutionary AI technology is available for use with leading digital breast
tomosynthesis systems in Europe. The solution is pending clearance by the United States Food and Drug
Administration (FDA). The company will showcase its latest innovations in
cancer detection at The European Society of Breast Imaging annual meeting in
booth 14 from October 11-13 at the Megaron Athens International Conference
Center, Megaro Mousikis Athinon in Athens, Greece.


About iCAD, Inc.


in Nashua, NH, iCAD is a global medical technology leader providing innovative
cancer detection and therapy solutions. For more information, visit


Harbor” Statement under the Private Securities Litigation Reform Act of


statements contained in this News Release constitute “forward-looking
statements” within the meaning of the Private Securities Litigation Reform Act
of 1995. Such forward-looking statements involve a number of known and unknown
risks, uncertainties and other factors which may cause the actual results,
performance or achievements of the Company to be materially different from any
future results, performance or achievements expressed or implied by such
forward-looking statements. Such factors include, but are not limited to the
Company’s ability to defend itself in litigation matters, to achieve business
and strategic objectives, the risks of uncertainty of patent protection, the
impact of supply and manufacturing constraints or difficulties, uncertainty of
future sales levels, protection of patents and other proprietary rights,
product market acceptance, possible technological obsolescence of products,
increased competition, litigation and/or government regulation, changes in
Medicare or other reimbursement policies, risks relating to our existing and
future debt obligations, competitive factors, the effects of a decline in the
economy or markets served by the Company; and other risks detailed in the
Company’s filings with the Securities and Exchange Commission. The words
“believe”, “demonstrate”, “intend”, “expect”, “would”, “could”, “consider”,
“project”, “estimate”, “will”, “continue”, “anticipate”, “likely”, “seek”, and
similar expressions identify forward-looking statements. Readers are cautioned not
to place undue reliance on those forward-looking statements, which speak only
as of the date the statement was made. The Company is under no obligation to
provide any updates to any information contained in this release. For
additional disclosure regarding these and other risks faced by iCAD, please see
the disclosure contained in our public filings with the Securities and Exchange
Commission, including the 10-K for the year ended December 31, 2017, available
on the Investors section of our website at and on the SEC’s website at




Media Inquiries:


ARPR, on behalf
of iCAD, Inc.

Paul Barren, +1
(855) 300-8209




Jeremy Feffer, +1
(212) 915-2568